Toggle navigation
About
Abstract
Editorial Board
Publication Schedule
Subscription & Newsletter
Contact
Issues
This issue
12-4
All issues
Download PDF
Download EPUB
Editor's Selection
This issue
12-4
Browse by topic
Browse by contributor
Dialogue & Opinion
Abstracts
Abstracts
Search
Classification List
Abstracted Journals
Index of Authors
News & Reports
Home
Abstracts
Journals
Journal #577
advertisement
Journal of Ocular Pharmacology and Therapeutics
3
Showing records 1 to 3 |
Display all abstracts in
Journal of Ocular Pharmacology and Therapeutics
27439
Association of CYP2D6 single-nucleotide polymorphism with response to ophthalmic timolol in primary open-angle glaucoma-a pilot study
Yuan H; Yu M; Yang Y; Wu K; Lin X; Li J
Journal of Ocular Pharmacology and Therapeutics
2010; 26: 497-501
27438
Effectiveness of dorzolamide-timolol (COSOPT) in patients who were treatment naive for open-angle glaucoma or ocular hypertension: The COSOPT first-line study
Crichton ACS; Harasymowycz P; Hutnik CML; Behki R; Boucher S; Ibrahim F; Rifkind AW; Solomon L; Liao C; Bastien NR
Journal of Ocular Pharmacology and Therapeutics
2010; 26: 503-511
27440
Effect of doxycycline on postoperative scarring after trabeculectomy in an experimental rabbit model
Sen E; Balikoglu-Yilmaz M; Bozdag-Pehlivan S; Sungu N; Aksakal FN; Altinok A; Tuna T; Unlu N; Ustun H; Koklu G
Journal of Ocular Pharmacology and Therapeutics
2010; 26: 399-406
Issue
12-4
Table of Contents
Editor's Selection
Change Issue
26-1
25-4
25-3
25-2
25-1
24-4
24-3
24-1/2
23-4
23-3
23-2
23-1
22-4
22-3
22-2
22-1
21-4
21-3
21-2
21-1
20-4
20-3
20-2
20-1
19-4
19-3
19-2
19-1
18-4
18-3
18-2
18-1
17-4
17-3
17-2
17-1
16-4
16-3
16-2
16-1
15-4
15-3
15-2
15-1
14-4
14-3
14-2
14-1
13-4
13-3
13-2
13-1
12-4
12-3
12-2
12-1
11-4
11-3
11-2
11-1
10-4
10-3
10-2
10-1
9-4
9-3
9-2
9-1
8-4
8-3
8-2
8-1
7-3
7-2
7-1
6-3
6-2
6-1
5-3
5-2
5-1
4-3
4-2
4-1
3-3
3-2
3-1
2-3
2-2
2-1
1-3
1-2
1-1
advertisement
We would like to use Google Analytics to see which parts of the review are read. It is only used to count visits, never for advertising.
Privacy statement
Decline
Accept